BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 17, 2026
See today's BioWorld Asia
Home
» Qyuns and Roche partner in $1B+ bispecific antibody deal
To read the full story,
subscribe
or
sign in
.
Qyuns and Roche partner in $1B+ bispecific antibody deal
Nov. 4, 2025
By
Marian (YoonJee) Chu
No Comments
Qyuns Therapeutics Co. Ltd. signed a potential $1.07 billion license deal with Roche Holding AG, granting the latter exclusive rights to QX-031N – a human thymic stromal lymphopoietin and interleukin-33)-targeting bispecific antibody.
BioWorld Asia
Deals and M&A
Immune
Respiratory
Bispecific antibody
Asia-Pacific
Europe
IND
NMPA
